Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-461 in Patient Volunteers With Hypertrophic Cardiomyopathy
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2016
At a glance
- Drugs Mavacamten (Primary)
- Indications Dilated cardiomyopathy; Hypertrophic cardiomyopathy
- Focus Adverse reactions
- Sponsors MyoKardia
- 16 Nov 2016 Results from NCT02329184 and NCT02356289 studies, presented at the 89th Annual Scientific Sessions of the American Heart Association.
- 11 Jul 2016 Results from this trial have been submitted for presentation at The American Heart Association's Scientific Sessions 2016, according to a MyoKardia media release.
- 11 Jul 2016 Results published in a MyoKardia media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History